← The Wire
ALKSNasdaq
Alkermes plc.
Pharmaceutical Preparations · CIK 1520262
Alkermes plc develops and commercializes medicines for diseases of the central nervous system and oncology
red 8-K · 90d
$7.38B
Market cap
$52.53
Last close
-4.6%
1D
+14.2%
5D
2.9M
Volume
Price · last 39 sessions+53.7%
May 4L $34.17 · H $55.08Jun 29
233
Total filings
Jun 15, 2026
Last filing
12/31
Fiscal year end
8-KReg FD Disclosure · Company UpdateJun 15, 20268-KExecutive Change · Shareholder VoteMay 20, 2026DEFA14ADEFA14AMay 13, 20268-KReg FD Disclosure · Company UpdateMay 12, 202610-Q10-QMay 5, 20268-KResults of OperationsMay 5, 20268-K/ACompany UpdateMay 1, 2026DEFA14ADEFA14AApr 6, 2026DEF 14ADEF 14AApr 6, 20268-KExecutive Change · Reg FD DisclosureFeb 25, 202610-K10-KFeb 25, 20268-KResults of OperationsFeb 25, 20268-KMaterial Agreement · Agreement TerminatedFeb 12, 20268-KResults of Operations · Reg FD DisclosureJan 12, 20268-KReg FD Disclosure · Company UpdateJan 6, 20268-KMaterial Agreement · New Debt / ObligationNov 19, 20258-KReg FD Disclosure · Company UpdateNov 12, 202510-Q10-QOct 28, 20258-KResults of OperationsOct 28, 20258-KMaterial Agreement · Results of OperationsOct 22, 20258-KMaterial Agreement · Company UpdateSep 12, 20258-KExecutive Change · Reg FD DisclosureSep 12, 20258-KReg FD DisclosureSep 8, 202510-Q10-QJul 29, 20258-KResults of OperationsJul 29, 20258-KReg FD DisclosureJul 21, 20258-KExecutive Change · Shareholder VoteMay 21, 2025DEFA14ADEFA14AMay 12, 202510-Q10-QMay 1, 20258-KResults of OperationsMay 1, 20258-KCompany UpdateApr 16, 2025DEFA14ADEFA14AApr 7, 2025DEF 14ADEF 14AApr 7, 202510-K10-KFeb 12, 20258-KResults of OperationsFeb 12, 20258-KResults of Operations · Reg FD DisclosureJan 13, 20258-KAgreement TerminatedDec 19, 20248-KReg FD DisclosureDec 2, 2024SC 13GSC 13GNov 14, 2024SC 13GSC 13GNov 4, 202410-Q10-QOct 24, 20248-KResults of OperationsOct 24, 20248-KReg FD DisclosureOct 9, 202410-Q10-QJul 24, 20248-KResults of OperationsJul 24, 20248-KExecutive Change · Shareholder VoteMay 31, 2024DEFA14ADEFA14AMay 14, 202410-Q10-QMay 1, 20248-KResults of OperationsMay 1, 2024DEFA14ADEFA14AApr 15, 2024DEF 14ADEF 14AApr 15, 20248-KReg FD DisclosureApr 9, 20248-KExecutive Change · Reg FD DisclosureMar 7, 202410-K10-KFeb 21, 20248-KResults of OperationsFeb 15, 2024SC 13GSEC SCHEDULE 13GFeb 8, 20248-KExecutive ChangeFeb 5, 2024SC 13GSC 13GJan 24, 20248-KReg FD DisclosureJan 8, 20248-KMaterial Agreement · Reg FD DisclosureDec 14, 20238-KExecutive ChangeDec 8, 20238-KMaterial Agreement · Acquisition / DispositionNov 15, 20238-KReg FD Disclosure · Company UpdateOct 31, 20238-KCompany UpdateOct 27, 202310-Q10-QOct 25, 20238-KResults of OperationsOct 25, 20238-KReg FD DisclosureOct 23, 20238-KMaterial Agreement · Reg FD DisclosureAug 30, 202310-Q10-QJul 26, 20238-KResults of OperationsJul 26, 20238-KExecutive Change · Shareholder VoteJul 6, 20238-KMaterial AgreementJul 5, 2023DEFA14AADDITIONAL DEFINITIVE MATERIALJun 26, 2023DEFA14ADEFA14AJun 26, 2023DEFA14ADEFA14AJun 26, 2023DEFA14AADDITIONAL DEFINITIVE MATERIALJun 21, 2023DEFA14AADDITIONAL DEFINITIVE MATERIALJun 21, 2023DEFA14ADEFA14AJun 21, 2023DEFA14AADDITIONAL DEFINITIVE MATERIALJun 20, 2023DEFA14ADEFA14AJun 20, 2023
Insider Activity
In the 90 days to Mar 3, 2026: 5 sold $3.6M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 3, 2026 | Gaffin David JosephEVP, CLO, Alkermes, Inc. | Sell | 2,034 | $29.76 | $61K |
| Mar 2, 2026 | Hopkinson Craig C.EVP R&D, Chief Medical Officer | Sell | 9,000 | $29.72 | $267K |
| Mar 2, 2026 | Parisi Samuel JosephVP, Finance (Interim PAO) | Sell | 6,890 | $29.29 | $202K |
| Mar 2, 2026 | Nichols Christian ToddSVP, Chief Commercial Officer | Sell | 6,000 | $30.00 | $180K |
| Mar 2, 2026 | Gaffin David JosephEVP, CLO, Alkermes, Inc. | Sell | 2,034 | $29.29 | $60K |
| Feb 2, 2026 | Cooke ShaneDirector | Sell | 32,113 | $34.78 | $1.1M |
| Feb 2, 2026 | Cooke ShaneDirector | Sell | 29,087 | $34.34 | $999K |
| Feb 2, 2026 | Hopkinson Craig C.EVP R&D, Chief Medical Officer | Sell | 5,000 | $34.24 | $171K |
| Feb 2, 2026 | Hopkinson Craig C.EVP R&D, Chief Medical Officer | Sell | 4,000 | $33.54 | $134K |
| Jan 8, 2026 | Hopkinson Craig C.EVP R&D, Chief Medical Officer | Sell | 5,000 | $30.00 | $150K |
| Jan 2, 2026 | Hopkinson Craig C.EVP R&D, Chief Medical Officer | Sell | 4,000 | $28.00 | $112K |
| Dec 3, 2025 | Hopkinson Craig C.EVP R&D, Chief Medical Officer | Sell | 3,748 | $30.00 | $112K |
| Dec 1, 2025 | Hopkinson Craig C.EVP R&D, Chief Medical Officer | Sell | 4,000 | $29.30 | $117K |
| Nov 3, 2025 | Hopkinson Craig C.EVP R&D, Chief Medical Officer | Sell | 9,000 | $30.38 | $273K |
| Oct 15, 2025 | Hopkinson Craig C.EVP R&D, Chief Medical Officer | Sell | 9,000 | $31.53 | $284K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance